daridorex high unmet need though
increas target price maintain neutral rate
daridorex increas po daridorex us
believ recent fda approv lemborex demonstr high unmet need new
class insomnia drug howev also believ investor might enthusiast
consid enough data yet conclud molecular properti individu
dora patient benefit
daridorex us commerci updat us forecast reflect
idorsia us commerci strategi go market contract sale
organ cso via out-licens see posit way go market
allow compani maintain control product busi strategi
remov potenti up-front payment out-licens exclud
increas royalti assum idorsia keep sale pay
royalti cso
capit rais continu see liquid gap break-even though
accord manag way rais capit equiti debt partnership
royalti bank consid equiti option stage howev adjust
refinanc price reflect stock upsid
move sinc last octob lead lower potenti dilut
deal decreas estim reflect delay
clinic trial well compani cost conscious opex sfr
includ recent mochida deal option model
catalyst phase data daridorex studi clazosentan japan
studi risk clinic trial regulatori risk
valuat target price per share base pharmavalu
methodolog risk-adjust dcf explicit forecast period ep
increas
valuat metric
number share
price rel chart measur perform
swiss market ind close
spot exchang rate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
idorsia biotechnolog compani focus therapeut agent
interact protein-coupl receptor idorsia demerg actelion
experienc employe state-of-the-art facil
prosper pipelin chf cash
scenario assum po aprocitentan
daridorex clazosentan lucerastat cenerimod
grey scenario assum lower sale aprocitentan
daridorex clazosentan lucerastat non-approv
price rel chart measur perform swiss market ind close
spot exchang rate
price
tp increas
increas target price reflect current market environ
stock sinc last octob fda approv lemborex recent deal
mochida option well compani cost conscious
believ recent approv lemborex demonstr high medic need new
class insomnia drug fewer side effect less addict potenti therefor
increas probabl success daridorex us howev
also believ investor might enthusiast consid enough data
yet clearli conclud dora superior see daridorex phase data import
catalyst
regard daridorex us commerci strategi idorsia commun
would commerci contract sale organ cso intent share risk
well success daridorex cso posit way go
market allow compani keep control product busi strategi
keep cost flexibl proport success rate sale rep also
believ share success/risk cso progress given current cso busi
fee servic phone call busi consequ poor incent reflect
intent remov potenti up-front payment assum
commerci via out-licens increas royalti assum idorsia keep
sale pay royalti cso
still see liquid gap break-even howev adjust
refinanc price reflect upsid move
share price sinc last octob lead lower potenti dilut
also decreas expens forecast reflect delay clinic trial
well compani current cost conscious quarterli spend
includ recent mochida deal option model
daridorex phase data import catalyst
daridorex one two blockbust candid idorsia cs estim ww peak sale
compani expect phase readout even though see
recent fda approv eisai lemborex clear sign unmet need new
class insomnia drug believ earli make conclus patient benefit
novel categori drug orexin antagonist data head-to-head studi necessari
make conclus individu dora categori gener knowledg
head-to-head data publish yet
current insomnia treatment expect orexin
insomnia market current consist gaba agent antidepress wherebi doctor
tri avoid prescrib gaba due danger side effect complex sleep
behavior memori loss next morn hangov effect well addict risk
symptom insomnia similar symptom depress depress comorbid
insomnia doctor tend prescrib anti-depress treat insomnia said
gener recommend treat comorbid condit first
hypothesi dora induc normal sleep less next-morn
hangov effect knock brain gaba block awaken
system also littl risk addict
head-to-head dora studi need conclud
molecul characterist patient benefit
half-lif next morn perform
experi belsomra show patient feel well-rest follow morn
hangov effect still present belsomra dora market
scientif commun believ characterist due long half-lif
molecul well sub-optimal dose howev patient data recent approv
lemborex show improv next morn drive perform despit longer half-lif
vs belsomra
said taken consider describ pattern shorter half-lif
better next day perform observ gaba agent howev gaba
complet differ mechan action agonist vs dora antagonist may
reason might true dora thu believ earli make
conclus yet daridorex data show whether molecul shorter half-lif
lead better next day perform believ head-to-head studi necessari
properli compar differ dora characterist
common advers event publish dora studi somnol
belsomra vs placebo suvorex phase studi dayvigo
vs dayvigo vs placebo lemborex phase studi compar
zolpidem common advers event control trial drowsi
dizzi diarrhea believ absenc somnol gaba
activ knock-out system dora block awaken system
believ quit high occurr turn regular use
dora mean regular block awaken system patient becom narcolept
would lead clearli neg patient experi dora gener howev evalu
safeti aspect data necessari
read across dayvigo approv daridorex
even though dora complet differ class drug compar gaba
recent fda approv dora lemborex contain complex sleep behavior warn
label vs explicit warn suvorex label though warn black
box warn label z-drug gaba zolpidem complex sleep behavior
one concern side effect believ fda becom
cautiou put warn daridorex label approv
furthermor suvorex carri schedul z-drug schedul iv drug low
potenti abus expect lemborex approv daridorex receiv
schedul mean less addict class/schedul gaba agent
capit rais
even though expect idorsia gross cash amount cse excl jnj
credit line balanc sheet end expect compani
reach break-even earliest assum oper expens reach around
per year lead need addit break-even accord
model includ manag plan around month runway rate
mean compani need rais capit year thu assum first capit
rais anoth round capit rais
accord manag blend instrument appli overcom liquid gap
manag howev guid amount capit rais timelin
option rais capit follow equiti capit market debt partnership royalti
bank see takeaway road page stage assum
rais equiti capit market due follow reason
exclud option debt moment idorsia alreadi convert bond
loan outstand togeth convert
assum substanti partnership stage compani announc
market plan contract sale organis daridorex cse ww peak sale
usd alreadi partner aprocitentan cse ww peak sale usd
plan commerci late stage asset clazosentan cse ww peak sale
usd lucerastat cse ww peak sale usd
drug far alreadi phase data publish outlicens
ponesimod cse ww peak sale usd idorsia entitl royalti
howev long file nda fda assum
transact perspect
said adjust refinanc equiti price capit rais
discount market price reflect upward move share
price sinc last octob lower potenti dilut contribut target price
takeaway road
last week host investor meet idorsia head ir andrew weiss expect
main focu daridorex cash situat
daridorex first phase studi studi readout second
phase studi studi readout file expect
long-term safeti trial on-going doesnt need complet finish file
clazosentan phase japan studi result parallel phase studi
run howev one need signific approv
lucerastat phase readout
aprocitentan phase readout toward end
cenerimod phase readout toward end
selatogrel phase studi kick presum
idorsia financ break-even consensu liquid gap sfr
compani cash burn sfr per year gross cash sfr
incl credit facil end mean idorsia
financ howev cfo prefer month runway henc
compani need rais capit possibl way wherebi
outcom could blend thereof way follow
capit rais howev clear yet whether public
first phase data also kept mind
founder jean-paul clozel own compani obvious
interest dilut stake
partnership up-front payment aprocitentan mochida
daridorex
sell part royalti one-tim payment royalti bank idorsia
exampl entitl royalti ponesimod out-licens
part -actelion deal publish posit phase data
septemb howev updat file yet
sharehold number retail sharehold doubl
accord manag idorsia wont first market dora molecul
best class
competit two fda approv dora far name belsomra suvorex
market merck dayvigo lemborex market eisai label
similar daridorex differenti approv dora shorter half-lif vs
suvorex vs lemborex base shorter half-lif manag
expect better next day perform profil daridorex competit come
seltorex develop outlicens
present phase data howev seltorex singl orexin receptor
antagonist sora plan time phase commun yet
commerci strategi us accord manag idorsia plan commerci
daridorex contract sale organis cso way would allow cso
particip success product also share risk compani
believ best way incentiv cso sale rep target market
gp market idorsia also discuss tech compani order receiv data
potenti patient popul on-line
price concret indic commun though price like
around market price belsomra whose list price
rebat howev idorsia want stay flexibl term price
japan mochida deal develop commerci daridorex japan
commun last decemb current idorsia run phase studi japan
howev insomnia drug reimburs environ japan difficult one
phase endpoint phase endpoint determin effect lucerastat
neuropath pain patient fabri diseas clinic endpoint measur
patient benefit reduct pain well biomark endpoint measur clearanc
structur clearanc suppos lead reduct pain howev
endpoint differ endpoint phase henc small risk whether work
rational develop lucerastat neuropath pain fabri patient
origin accumul un-degrad metabolit within nerv cell
lucerastat small enough iminosugar cross blood brain barrier thu
effect nerv cell activ molecul exist therapi
enzym replac therapi ert small enough cross barrier henc
effect neuropath pain
delay phase trial commun phase trial lucerastat
delay one possibl explic therefor doctor perceiv lucerastat
pain killer believ reason treat fabri patient lucerastat
howev lucerastat paracetamol disease-modifi agent effect
impli idorsia need work educ doctor lucerastat
includ new deal mochida regard develop potenti
commerci daridorex japan includ up-front payment
assum develop mileston time phase
phase file well commerci mileston royalti
probabl also postpon potenti launch daridorex
japan
increas probabl success daridorex us
believ fda approv lemborex demonstr high unmet need new
class insomnia drug besid adjust us commerci strategi
daridorex reflect current market plan contract sale organ
cso remov forecast up-front payment increas econom sale
assumpt idorsia keep sale pay cso
includ option
decreas expens around around
go forward reflect compani cost conscious well recent
deal also affect develop cost
reflect current market environ adjust refinanc price two
potenti capit rais
includ discount
figur chang forecast
figur chang npv
valu idorsia use pharmavalu method base sum-of-the-part
npv product opex mileston cash
increas target price per share mainli driven increas po
daridorex higher royalti daridorex due updat commerci strategi
higher refinanc price capit rais reduc expens due
price move grey price
scenario assum probabl success
aprocitentan daridorex clazosentan lucerastat cenerimod keep
estim base case scenario grey scenario assum lower sale
aprocitentan daridorex clazosentan lucerastat non-approv cenerimod
keep estim base case scenario
figur npv sotp
npv usd old cash break-even cse op burn shae per charl martineau pm univers toronto januari
sale usd posecon launchpeak sale risk-adj econ product sale mileston risk-adj econ market chf idorsia oper incom net share report fulli charl martineau pm univers toronto januari
 accret convert loan/bond discount loss market secur work cash oper sale short-term sale long-term purchas intang asset market cash invest dividend sharehold equiti capit rais issuanc new issuanc convert loan net issuanc convert bond net cash financ fx gain loss cash cash chang cash cash cash equival begin cash equival end short-term current tax current current non-curr use assetslong-term non-curr revenu current revenu liabilitypens liabil employe non-curr non-curr equiti charl martineau pm univers toronto januari
compani mention price
barbora blaha certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
